Men with Low-Risk Prostate Cancer: Expectant Management, with Curative Intent
The downside to prostate cancer screening is that, for some men, it's too good: It finds cancer that probably doesn't need to be found. "There is a tradeoff," says H. Ballentine Carter, M.D., professor of urology and oncology. "Some men are diagnosed and treated unnecessarily." In these men, prostate cancer is very slow-growing. It never spreads beyond the prostate, and never becomes aggressive.
About half of men today are diagnosed with this "low-risk" prostate cancer — cancer that is too small to be felt during a rectal exam, with a Gleason score of 6 or lower, in men with a PSA below 10 nanograms per milliliter. "This is going to be an increasing issue as our population ages, and as more men undergo regular screening for prostate cancer," Carter says.
This is not watchful waiting, it’s
Some of these men, Carter believes, may be ideal candidates for something new. "Starting with the assumption that men with low-risk prostate cancer can almost always be cured with surgery, and that for younger men, surgery is ideal, there is a subset of older men for whom expectant management with curative intent may be an ideal option, because of the low risk of disease progression." This is not watchful waiting; it's proactive monitoring.
Carter, who is leading the research in this new area, started a program at Hopkins in 1995 designed to identify men with low-risk prostate cancer, follow them closely, and intervene with curative intent (surgery or radiation) only if the disease progresses. Over the last decade, about 400 men, with an average age of 67, have entered this program. First, these men undergo at least a 12-core biopsy, to make sure their disease has not been underestimated. Then, they are followed closely, with a PSA and rectal examination every six months, and a yearly biopsy. Progression is defined by what the pathologist sees in the biopsy — cancer present in more than two cores, or in more than half of any one core; or a Gleason score of 7 or greater — or an unusual increase in PSA that prompts another biopsy.
"The trigger for intervention in these men is biopsy evidence that there is more disease, or higher-grade disease," Carter says.But what about the critical "window of curability?" Could men miss their chance of being cured, even with this close monitoring? Carter and colleagues recently addressed this question in a study, published in the Journal of the National Cancer Institute. "We compared the surgical outcomes of 38 men who entered the surveillance program and subsequently underwent surgery — on average, two to three years later — with 150 similar men who qualified for the program but chose to undergo surgery immediately after their diagnosis." The scientists found that an equal number of men in both groups turned out to have curable disease.
Carter stresses that this approach is still investigational. However, so far — using this careful plan for enrolling patients and following them — it does not appear that the window of curability is being lost.